The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
iodine I 125
A radioactive isotope of iodine, a nonmetallic element of the halogen
group. With a half-life of 60 days, iodine 125 occurs naturally and can
be produced artificially. This agent has both therapeutic and
diagnostic uses, particularly in thyroid disease.